Julian Beezhold
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julian Beezhold has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
- Jerzy Samochowiec
Pomeranian Medical University in Szczecin: Pomorski Uniwersytet Medyczny w Szcze
7 shared publications - Martina Rojnic Kuzman
University Hospital Centre Zagreb: Klinicki Bolnicki Centar Zagreb
7 shared publications - Andrea Fiorillo
Department of Psychiatry, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy
6 shared publications - Philip Gorwood
Universite Paris Cite
6 shared publications - Geert Dom
University of Antwerp: Universiteit Antwerpen
5 shared publications - Pavel Mohr
Charles University Third Faculty of Medicine: Univerzita Karlova
5 shared publications
Latest Publications
- Open Access
- 16 February 2026
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 69 (1) , 1-27
Rethinking Schizophrenia: Optimizing Care Pathways in Europe from the First Episode of Psychosis to Long-Term Care
Background: The European Brain Council project “Rethinking Schizophrenia” aims to examine the existing state of patient care pathways across Europe. The study objectives of Phase 2 were to evaluate the current models of schizophrenia care on mental health outcomes, access and satisfaction with care, and to identify the foundations of integrated care pathways for young people with first-episode psychosis. Methods: Using the care pathway, a questionnaire was developed and anonymously disseminated to mental health professionals in nine European countries (Belgium, Denmark, France, Germany, Hungary, Italy, Poland, Spain, and the United Kingdom). The survey included 45 questions and addressed the quality and continuity of care from the first onset of psychosis to long-term care, including assessment of the mental health care systems. Results: A total of 203 responses were obtained. The majority of mental health professionals were psychiatrists (75%), followed by psychologists (11%), nurses (7%), social workers (2%), and GPs and others (5%). The responses were analyzed qualitatively. The results revealed dissatisfaction with the current state of schizophrenia care systems and significant variability in quality of care. The factors that affect the care pathways most are assessment and early intervention services, continuity of care, availability of various types of services and treatments, collaborative decision-making, and utilization of new technologies. Conclusions: A comprehensive, integrated approach is essential to improve schizophrenia care across Europe. This strategy emphasizes early intervention, equitable access to treatments, coordinated care models, psychosocial support, and long-term recovery through a biopsychosocial framework and emerging technologies.
- 16 February 2026
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 69 (1) , 1-27
Open AccessRethinking Schizophrenia: Optimizing Care Pathways in Europe from the First Episode of Psychosis to Long-Term Care
Background: The European Brain Council project “Rethinking Schizophrenia” aims to examine the existing state of patient care pathways across Europe. The study objectives of Phase 2 were to evaluate the current models of schizophrenia care on mental health outcomes, access and satisfaction with care, and to identify the foundations of integrated care pathways for young people with first-episode psychosis. Methods: Using the care pathway, a questionnaire was developed and anonymously disseminated to mental health professionals in nine European countries (Belgium, Denmark, France, Germany, Hungary, Italy, Poland, Spain, and the United Kingdom). The survey included 45 questions and addressed the quality and continuity of care from the first onset of psychosis to long-term care, including assessment of the mental health care systems. Results: A total of 203 responses were obtained. The majority of mental health professionals were psychiatrists (75%), followed by psychologists (11%), nurses (7%), social workers (2%), and GPs and others (5%). The responses were analyzed qualitatively. The results revealed dissatisfaction with the current state of schizophrenia care systems and significant variability in quality of care. The factors that affect the care pathways most are assessment and early intervention services, continuity of care, availability of various types of services and treatments, collaborative decision-making, and utilization of new technologies. Conclusions: A comprehensive, integrated approach is essential to improve schizophrenia care across Europe. This strategy emphasizes early intervention, equitable access to treatments, coordinated care models, psychosocial support, and long-term recovery through a biopsychosocial framework and emerging technologies.
- Open Access
- 26 January 2026
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 69 (1) , 1-10
Professional burnout syndrome in European primary care doctors: A joint call for system-level action between the European Psychiatric Association (EPA) and the World Organization of National Colleges, Academies and Academic Associations of General Practitioners/Family Physicians-Europe Region (WONCA Europe)
Professional burnout syndrome represents a significant occupational hazard within European primary care physicians, impacting their well-being, quality of care, and the sustainability of healthcare systems. This joint European Psychiatric Association (EPA) and the World Organization of National Colleges, Academies and Academic Associations of General Practitioners/Family Physicians- Europe Region (WONCA Europe) viewpoint focuses specifically on primary care physicians, contrasts their risk profile with other specialties, and outlines actionable, system-level recommendations for policymakers, provider organizations, and professional associations. Evidence indicates a wide range in professional burnout syndrome prevalence, influenced by assessment methodologies and specific national contexts. The syndrome manifests through emotional exhaustion, depersonalization, and reduced personal accomplishment, often accompanied by secondary psychological and physical symptoms. A multitude of interacting risk factors at the individual, interpersonal, and organizational levels contribute to its development. Effective mitigation strategies necessitate a multi-pronged approach encompassing individual coping mechanisms and systemic organizational changes aimed at alleviating workload, enhancing autonomy, and fostering supportive work environments.
- 26 January 2026
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 69 (1) , 1-10
Open AccessProfessional burnout syndrome in European primary care doctors: A joint call for system-level action between the European Psychiatric Association (EPA) and the World Organization of National Colleges, Academies and Academic Associations of General Practitioners/Family Physicians-Europe Region (WONCA Europe)
Professional burnout syndrome represents a significant occupational hazard within European primary care physicians, impacting their well-being, quality of care, and the sustainability of healthcare systems. This joint European Psychiatric Association (EPA) and the World Organization of National Colleges, Academies and Academic Associations of General Practitioners/Family Physicians- Europe Region (WONCA Europe) viewpoint focuses specifically on primary care physicians, contrasts their risk profile with other specialties, and outlines actionable, system-level recommendations for policymakers, provider organizations, and professional associations. Evidence indicates a wide range in professional burnout syndrome prevalence, influenced by assessment methodologies and specific national contexts. The syndrome manifests through emotional exhaustion, depersonalization, and reduced personal accomplishment, often accompanied by secondary psychological and physical symptoms. A multitude of interacting risk factors at the individual, interpersonal, and organizational levels contribute to its development. Effective mitigation strategies necessitate a multi-pronged approach encompassing individual coping mechanisms and systemic organizational changes aimed at alleviating workload, enhancing autonomy, and fostering supportive work environments.
- Open Access
- 24 November 2025
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 68 (1) , 1-35
Suicide prediction, prevention, and the blame culture: A narrative review based on trends in mortality rates
Background: Suicide involves an act of volition on the part of the deceased, making it unlike deaths from physical disorders such as cancer or stroke. The latter occur passively and often despite the efforts of the patient to stay alive. Yet when there is a suicide, clinicians involved may often be blamed and families may often feel guilt. This contrasts with the default response of praise and thanks to clinicians following treatment preceding deaths from physical disorders. Methods: Comparative standardized mortality rate (SMR) data are analyzed to demonstrate the impact of developments in care over the past two decades in the United Kingdom (UK), and similar United States (USA) SMR data are noted. The evidence is reviewed regarding our ability to predict who will die by suicide, when and where to target intervention, and practical and effective prevention methods. Results: Data from the UK are presented that reflects the relative lack of impact of prevention efforts on suicide mortality rates when compared to the reductions seen in various physical disorders. This narrative review comments on the causes and consequences of this difference. Conclusions: The challenge for psychiatry is that SMR data suggest that we have been unable to significantly reduce suicide SMR unlike that for physical disorders. This needs to be fully acknowledged and the biased assumption of blame needs to stop. The focus needs to be on evidence-based interventions that do work, such as medications, psychological treatments, psychological interventions, and suicide prevention research.
- 24 November 2025
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 68 (1) , 1-35
Open AccessSuicide prediction, prevention, and the blame culture: A narrative review based on trends in mortality rates
Background: Suicide involves an act of volition on the part of the deceased, making it unlike deaths from physical disorders such as cancer or stroke. The latter occur passively and often despite the efforts of the patient to stay alive. Yet when there is a suicide, clinicians involved may often be blamed and families may often feel guilt. This contrasts with the default response of praise and thanks to clinicians following treatment preceding deaths from physical disorders. Methods: Comparative standardized mortality rate (SMR) data are analyzed to demonstrate the impact of developments in care over the past two decades in the United Kingdom (UK), and similar United States (USA) SMR data are noted. The evidence is reviewed regarding our ability to predict who will die by suicide, when and where to target intervention, and practical and effective prevention methods. Results: Data from the UK are presented that reflects the relative lack of impact of prevention efforts on suicide mortality rates when compared to the reductions seen in various physical disorders. This narrative review comments on the causes and consequences of this difference. Conclusions: The challenge for psychiatry is that SMR data suggest that we have been unable to significantly reduce suicide SMR unlike that for physical disorders. This needs to be fully acknowledged and the biased assumption of blame needs to stop. The focus needs to be on evidence-based interventions that do work, such as medications, psychological treatments, psychological interventions, and suicide prevention research.
- Open Access
- 13 October 2025
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 68 (1) , 1-10
Protection of human rights during involuntary treatment in mental healthcare services: A European perspective
Involuntary placement and treatment within mental healthcare represent one of the most sensitive areas where clinical needs and human rights intersect and the protection of fundamental rights of individuals subjected to coercive measures remains a paramount concern. This issue has been along-standing interest of the European Psychiatric Association (EPA), reflected in studies conducted by the EPA members and by the EPA Code of Ethics. Moreover, the EPA supports the work of the Parliamentary Assembly of the Council of Europe on a Draft Additional Protocol to the Convention on Human Rights and Biomedicine, as an European document aiming to harmonize practice across Europe, emphasizing involuntary treatment as a last resort, guaranteeing access to legal counsel, and ensuring continuous monitoring. However, weemphasize several aspects that should be included: 1) future reforms must integrate legalsafeguards with innovations in community care and evidence-based practice, ensuring that involuntary measures remain exceptional and rigorously justified; 2) while evidence-based strategies to reduce coercive treatment exist, it is important to emphasize the need for regular staff training, knowledge exchange, and consistent application of high standards, with a focus on minimizing the use of involuntary treatment within facilities while developing alternatives; 3)coercive treatment is regularly used in general hospitals for patients lacking decision-making capacity. Addressing all involuntary treatment, in both psychiatric and other healthcare settings, to ensure that the same legal, ethical and clinical values and standards are applied to all, is also critical in order to confine coercion to the absolute minimum.
- 13 October 2025
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 68 (1) , 1-10
Open AccessProtection of human rights during involuntary treatment in mental healthcare services: A European perspective
Involuntary placement and treatment within mental healthcare represent one of the most sensitive areas where clinical needs and human rights intersect and the protection of fundamental rights of individuals subjected to coercive measures remains a paramount concern. This issue has been along-standing interest of the European Psychiatric Association (EPA), reflected in studies conducted by the EPA members and by the EPA Code of Ethics. Moreover, the EPA supports the work of the Parliamentary Assembly of the Council of Europe on a Draft Additional Protocol to the Convention on Human Rights and Biomedicine, as an European document aiming to harmonize practice across Europe, emphasizing involuntary treatment as a last resort, guaranteeing access to legal counsel, and ensuring continuous monitoring. However, weemphasize several aspects that should be included: 1) future reforms must integrate legalsafeguards with innovations in community care and evidence-based practice, ensuring that involuntary measures remain exceptional and rigorously justified; 2) while evidence-based strategies to reduce coercive treatment exist, it is important to emphasize the need for regular staff training, knowledge exchange, and consistent application of high standards, with a focus on minimizing the use of involuntary treatment within facilities while developing alternatives; 3)coercive treatment is regularly used in general hospitals for patients lacking decision-making capacity. Addressing all involuntary treatment, in both psychiatric and other healthcare settings, to ensure that the same legal, ethical and clinical values and standards are applied to all, is also critical in order to confine coercion to the absolute minimum.
- Open Access
- 3 September 2025
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 68 (1) , 1-61
Urban mental health: a position paper of the European psychiatric association
Background: Urbanization, the shift of a growing population into urban areas, is shaping global development across infrastructure, health, and sustainability. Although it brings economic growth, innovation, and improved access to services, it may also impact mental health. Methods: The present article was prepared on behalf of the European Psychiatric Association and explores the complexity of associations between urbanization and mental health, highlighting both potential risks and opportunities for improvement. Results: Urban growth often leads to increased population density, social fragmentation, and environmental stressors, including noise, pollution, and reduced green spaces, all of which might account for worsening mental health. Urban residents might be at risk of various mental disorders due to these stressors, accompanied by the risk of social disconnection. Moreover, socioeconomic disparities in urban settings can lead to unequal healthcare access, further contributing to these challenges. However, urbanization also offers unique opportunities to improve mental health through better resource allocation, innovative healthcare solutions, and community-building initiatives. Indeed, cities might serve as areas for mental health promotion by integrating mental health services into primary care, utilizing digital health technologies, and fostering environments that promote social interactions and well-being. Urban planning that prioritizes green spaces, safe housing, and accessible public transportation holds the potential to mitigate some risks related to urban living. Conclusions: While urbanization presents significant challenges to mental health, it also provides grounds for transformative interventions. Addressing the mental health needs of urban populations requires a multifaceted approach that includes policy reform, community engagement, and sustainable urban planning.
- 3 September 2025
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 68 (1) , 1-61
Open AccessUrban mental health: a position paper of the European psychiatric association
Background: Urbanization, the shift of a growing population into urban areas, is shaping global development across infrastructure, health, and sustainability. Although it brings economic growth, innovation, and improved access to services, it may also impact mental health. Methods: The present article was prepared on behalf of the European Psychiatric Association and explores the complexity of associations between urbanization and mental health, highlighting both potential risks and opportunities for improvement. Results: Urban growth often leads to increased population density, social fragmentation, and environmental stressors, including noise, pollution, and reduced green spaces, all of which might account for worsening mental health. Urban residents might be at risk of various mental disorders due to these stressors, accompanied by the risk of social disconnection. Moreover, socioeconomic disparities in urban settings can lead to unequal healthcare access, further contributing to these challenges. However, urbanization also offers unique opportunities to improve mental health through better resource allocation, innovative healthcare solutions, and community-building initiatives. Indeed, cities might serve as areas for mental health promotion by integrating mental health services into primary care, utilizing digital health technologies, and fostering environments that promote social interactions and well-being. Urban planning that prioritizes green spaces, safe housing, and accessible public transportation holds the potential to mitigate some risks related to urban living. Conclusions: While urbanization presents significant challenges to mental health, it also provides grounds for transformative interventions. Addressing the mental health needs of urban populations requires a multifaceted approach that includes policy reform, community engagement, and sustainable urban planning.
- Open Access
- 1 August 2025
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 68 (1) , 1-50
Schizophrenia treatment preferences of psychiatrists versus guidelines: A European perspective
Background: We aimed to identify therapeutic approaches for managing schizophrenia in different phases and clinical situations – the prodromal phase, first-episode psychosis, cognitive and negative symptoms, pregnancy, treatment resistance, and antipsychotic-induced metabolic side effects – while assessing clinicians’ adherence to guidelines. Methods: A cross-sectional online survey was conducted in 2023 as part of the Ambassador project among psychiatrists and trainees from 35 European countries, based on a questionnaire that included six clinical vignettes (cases A–F). Additionally, a review of multiple guidelines/guidance papers was performed. Results: The final analysis included 454 participants. Our findings revealed a moderate to high level of agreement among European psychiatrists regarding pharmacological treatment preferences for first-episode psychosis and cognitive and negative symptoms, prodromal symptoms and pregnancy, with moderate adherence to clinical guidelines. There was substantial similarity in treatment preferences for antipsychotic-induced metabolic side effects and treatment resistance; however, adherence to guidelines in these areas was only partial. Despite guideline recommendations, non-pharmacological treatments, including psychotherapy and recovery-oriented care, were generally underutilized, except for psychoeducation and lifestyle recommendations, and cognitive behavioural therapy for treatment of the prodromal phase. Contrary to guidelines, cognitive remediation and physical exercise for cognitive symptoms were significantly neglected. Conclusions: These discrepancies highlight the need for effective implementation strategies to bridge the gap between research evidence, clinical guidelines/guidance papers, and real-world clinical practice. Clinicians’ unique combination of knowledge and experience positions them to shape future guidelines, especially where real-world practice diverges from recommendations, reinforcing the need to integrate both research evidence and clinical consensus.
- 1 August 2025
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 68 (1) , 1-50
Open AccessSchizophrenia treatment preferences of psychiatrists versus guidelines: A European perspective
Background: We aimed to identify therapeutic approaches for managing schizophrenia in different phases and clinical situations – the prodromal phase, first-episode psychosis, cognitive and negative symptoms, pregnancy, treatment resistance, and antipsychotic-induced metabolic side effects – while assessing clinicians’ adherence to guidelines. Methods: A cross-sectional online survey was conducted in 2023 as part of the Ambassador project among psychiatrists and trainees from 35 European countries, based on a questionnaire that included six clinical vignettes (cases A–F). Additionally, a review of multiple guidelines/guidance papers was performed. Results: The final analysis included 454 participants. Our findings revealed a moderate to high level of agreement among European psychiatrists regarding pharmacological treatment preferences for first-episode psychosis and cognitive and negative symptoms, prodromal symptoms and pregnancy, with moderate adherence to clinical guidelines. There was substantial similarity in treatment preferences for antipsychotic-induced metabolic side effects and treatment resistance; however, adherence to guidelines in these areas was only partial. Despite guideline recommendations, non-pharmacological treatments, including psychotherapy and recovery-oriented care, were generally underutilized, except for psychoeducation and lifestyle recommendations, and cognitive behavioural therapy for treatment of the prodromal phase. Contrary to guidelines, cognitive remediation and physical exercise for cognitive symptoms were significantly neglected. Conclusions: These discrepancies highlight the need for effective implementation strategies to bridge the gap between research evidence, clinical guidelines/guidance papers, and real-world clinical practice. Clinicians’ unique combination of knowledge and experience positions them to shape future guidelines, especially where real-world practice diverges from recommendations, reinforcing the need to integrate both research evidence and clinical consensus.
- Open Access
- 7 March 2024
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 67 (1) , 1-47
Clinician treatment choices for post-traumatic stress disorder: ambassadors survey of psychiatrists in 39 European countries
Background: Considering the recently growing number of potentially traumatic events in Europe, the European Psychiatric Association undertook a study to investigate clinicians’ treatment choices for post-traumatic stress disorder (PTSD). Methods: The case-based analysis included 611 participants, who correctly classified the vignette as a case of PTSD, from Central/ Eastern Europe (CEE) (n = 279), Southern Europe (SE) (n = 92), Northern Europe (NE) (n = 92), and Western Europe (WE) (N = 148). Results: About 82% woulduse antidepressants (sertraline being the most preferred one). Benzodiazepines and antipsychotics were significantly more frequently recommended by participants from CEE (33 and 4%, respectively), compared to participants from NE (11 and 0%) and SE (9% and 3%). About 52% of clinicians recommended trauma-focused cognitive behavior therapy and 35% psychoeducation, irrespective of their origin. In the latent class analysis, we identified four distinct “profiles” of clinicians. In Class 1 (N = 367), psychiatrists would less often recommend any antidepressants. In Class 2 (N = 51), clinicians would recommend trazodone and prolonged exposure therapy. In Class 3 (N = 65), they propose mirtazapine and eye movement desensitization reprocessing therapy. In Class 4 (N = 128), clinicians propose different types of medications and cognitive processing therapy. About 50.1% of participants in each region stated they do not adhere to recognized treatment guidelines. Conclusions: Clinicians’ decisions for PTSD are broadly similar among European psychiatrists, but regional differences suggest the need for more dialogue and education to harmonize practice across Europe and promote the use of guidelines.
- 7 March 2024
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 67 (1) , 1-47
Open AccessClinician treatment choices for post-traumatic stress disorder: ambassadors survey of psychiatrists in 39 European countries
Background: Considering the recently growing number of potentially traumatic events in Europe, the European Psychiatric Association undertook a study to investigate clinicians’ treatment choices for post-traumatic stress disorder (PTSD). Methods: The case-based analysis included 611 participants, who correctly classified the vignette as a case of PTSD, from Central/ Eastern Europe (CEE) (n = 279), Southern Europe (SE) (n = 92), Northern Europe (NE) (n = 92), and Western Europe (WE) (N = 148). Results: About 82% woulduse antidepressants (sertraline being the most preferred one). Benzodiazepines and antipsychotics were significantly more frequently recommended by participants from CEE (33 and 4%, respectively), compared to participants from NE (11 and 0%) and SE (9% and 3%). About 52% of clinicians recommended trauma-focused cognitive behavior therapy and 35% psychoeducation, irrespective of their origin. In the latent class analysis, we identified four distinct “profiles” of clinicians. In Class 1 (N = 367), psychiatrists would less often recommend any antidepressants. In Class 2 (N = 51), clinicians would recommend trazodone and prolonged exposure therapy. In Class 3 (N = 65), they propose mirtazapine and eye movement desensitization reprocessing therapy. In Class 4 (N = 128), clinicians propose different types of medications and cognitive processing therapy. About 50.1% of participants in each region stated they do not adhere to recognized treatment guidelines. Conclusions: Clinicians’ decisions for PTSD are broadly similar among European psychiatrists, but regional differences suggest the need for more dialogue and education to harmonize practice across Europe and promote the use of guidelines.
- Open Access
- 3 August 2023
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 66 (1) , 1-22
Improving mental health care in depression: A call for action
Depressive disorders have one of the highest disability-adjusted life years (DALYs) of all medical conditions, which led the European Psychiatric Association to propose a policy paper, pinpointing their unmet health care and research needs. The first part focuses on what can be currently done to improve the care of patients with depression, and then discuss future trends for research and healthcare. Through the narration of clinical cases, the different points are illustrated. The necessary political framework is formulated, to implement such changes to fundamentally improve psychiatric care. The group of European Psychiatrist Association (EPA) experts insist on the need for (1) increased awareness of mental illness in primary care settings, (2) the development of novel (biological) markers, (3) the rapid implementation of machine learning (supporting diagnostics, prognostics, and therapeutics), (4) the generalized use of electronic devices and apps into everyday treatment, (5) the development of the new generation of treatment options, such as plasticity-promoting agents, and (6) the importance of comprehensive recovery approach. At a political level, the group also proposed four priorities, the need to (1) increase the use of open science, (2) implement reasonable data protection laws, (3) establish ethical electronic health records, and (4) enable better healthcare research and saving resources.
- 3 August 2023
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 66 (1) , 1-22
Open AccessImproving mental health care in depression: A call for action
Depressive disorders have one of the highest disability-adjusted life years (DALYs) of all medical conditions, which led the European Psychiatric Association to propose a policy paper, pinpointing their unmet health care and research needs. The first part focuses on what can be currently done to improve the care of patients with depression, and then discuss future trends for research and healthcare. Through the narration of clinical cases, the different points are illustrated. The necessary political framework is formulated, to implement such changes to fundamentally improve psychiatric care. The group of European Psychiatrist Association (EPA) experts insist on the need for (1) increased awareness of mental illness in primary care settings, (2) the development of novel (biological) markers, (3) the rapid implementation of machine learning (supporting diagnostics, prognostics, and therapeutics), (4) the generalized use of electronic devices and apps into everyday treatment, (5) the development of the new generation of treatment options, such as plasticity-promoting agents, and (6) the importance of comprehensive recovery approach. At a political level, the group also proposed four priorities, the need to (1) increase the use of open science, (2) implement reasonable data protection laws, (3) establish ethical electronic health records, and (4) enable better healthcare research and saving resources.
- Open Access
- 21 October 2022
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 65 (1) , 1-33
Clinical decision-making style preferences of European psychiatrists: Results from the Ambassadors survey in 38 countries
Background While shared clinical decision-making (SDM) is the preferred approach to decision-making in mental health care, its implementation in everyday clinical practice is still insufficient. The European Psychiatric Association undertook a study aiming to gather data on the clinical decision-making style preferences of psychiatrists working in Europe. Methods We conducted a cross-sectional online survey involving a sample of 751 psychiatrists and psychiatry specialist trainees from 38 European countries in 2021, using the Clinical Decision-Making Style - Staff questionnaire and a set of questions regarding clinicians' expertise, training, and practice. Results SDM was the preferred decision-making style across all European regions ([central and eastern Europe, CEE], northern and western Europe [NWE], and southern Europe [SE]), with an average of 73% of clinical decisions being rated as SDM. However, we found significant differences in non-SDM decision-making styles: participants working in NWE countries more often prefer shared and active decision-making styles rather than passive styles when compared to other European regions, especially to the CEE. Additionally, psychiatry specialist trainees (compared to psychiatrists), those working mainly with outpatients (compared to those working mainly with inpatients) and those working in community mental health services/public services (compared to mixed and private settings) have a significantly lower preference for passive decision-making style. Conclusions The preferences for SDM styles among European psychiatrists are generally similar. However, the identified differences in the preferences for non-SDM styles across the regions call for more dialogue and educational efforts to harmonize practice across Europe.
- 21 October 2022
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 65 (1) , 1-33
Open AccessClinical decision-making style preferences of European psychiatrists: Results from the Ambassadors survey in 38 countries
Background While shared clinical decision-making (SDM) is the preferred approach to decision-making in mental health care, its implementation in everyday clinical practice is still insufficient. The European Psychiatric Association undertook a study aiming to gather data on the clinical decision-making style preferences of psychiatrists working in Europe. Methods We conducted a cross-sectional online survey involving a sample of 751 psychiatrists and psychiatry specialist trainees from 38 European countries in 2021, using the Clinical Decision-Making Style - Staff questionnaire and a set of questions regarding clinicians' expertise, training, and practice. Results SDM was the preferred decision-making style across all European regions ([central and eastern Europe, CEE], northern and western Europe [NWE], and southern Europe [SE]), with an average of 73% of clinical decisions being rated as SDM. However, we found significant differences in non-SDM decision-making styles: participants working in NWE countries more often prefer shared and active decision-making styles rather than passive styles when compared to other European regions, especially to the CEE. Additionally, psychiatry specialist trainees (compared to psychiatrists), those working mainly with outpatients (compared to those working mainly with inpatients) and those working in community mental health services/public services (compared to mixed and private settings) have a significantly lower preference for passive decision-making style. Conclusions The preferences for SDM styles among European psychiatrists are generally similar. However, the identified differences in the preferences for non-SDM styles across the regions call for more dialogue and educational efforts to harmonize practice across Europe.
- Open Access
- 11 August 2022
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 65 (1) , e47
Joint European policy on the COVID-19 risks for people with mental disorders: An umbrella review and evidence- and consensus-based recommendations for mental and public health
As COVID-19 becomes endemic, identifying vulnerable population groups for severe infection outcomes and defining rapid and effective preventive and therapeutic strategies remains a public health priority. We performed an umbrella review, including comprehensive studies (meta-analyses and systematic reviews) investigating COVID-19 risk for infection, hospitalization, intensive care unit (ICU) admission, and mortality in people with psychiatric disorders, and outlined evidence- and consensus-based recommendations for overcoming potential barriers that psychiatric patients may experience in preventing and managing COVID-19, and defining optimal therapeutic options and current research priorities in psychiatry. We searched Web of Science, PubMed, and Ovid/PsycINFO databases up to 17 January 2022 for the umbrella review. We synthesized evidence, extracting when available pooled odd ratio estimates for the categories “any mental disorder” and “severe mental disorders.” The quality of each study was assessed using the AMSTAR-2 approach and ranking evidence quality. We identified four systematic review/meta-analysis combinations, one meta-analysis, and three systematic reviews, each including up to 28 original studies. Although we rated the quality of studies from moderate to low and the evidence ranged from highly suggestive to non-significant, we found consistent evidence that people with mental illness are at increased risk of COVID-19 infection, hospitalization, and most importantly mortality, but not of ICU admission. The risk and the burden of COVID-19 in people with mental disorders, in particular those with severe mental illness, can no longer be ignored but demands urgent targeted and persistent action. Twenty-two recommendations are proposed to facilitate this process.
- 11 August 2022
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 65 (1) , e47
Open AccessJoint European policy on the COVID-19 risks for people with mental disorders: An umbrella review and evidence- and consensus-based recommendations for mental and public health
As COVID-19 becomes endemic, identifying vulnerable population groups for severe infection outcomes and defining rapid and effective preventive and therapeutic strategies remains a public health priority. We performed an umbrella review, including comprehensive studies (meta-analyses and systematic reviews) investigating COVID-19 risk for infection, hospitalization, intensive care unit (ICU) admission, and mortality in people with psychiatric disorders, and outlined evidence- and consensus-based recommendations for overcoming potential barriers that psychiatric patients may experience in preventing and managing COVID-19, and defining optimal therapeutic options and current research priorities in psychiatry. We searched Web of Science, PubMed, and Ovid/PsycINFO databases up to 17 January 2022 for the umbrella review. We synthesized evidence, extracting when available pooled odd ratio estimates for the categories “any mental disorder” and “severe mental disorders.” The quality of each study was assessed using the AMSTAR-2 approach and ranking evidence quality. We identified four systematic review/meta-analysis combinations, one meta-analysis, and three systematic reviews, each including up to 28 original studies. Although we rated the quality of studies from moderate to low and the evidence ranged from highly suggestive to non-significant, we found consistent evidence that people with mental illness are at increased risk of COVID-19 infection, hospitalization, and most importantly mortality, but not of ICU admission. The risk and the burden of COVID-19 in people with mental disorders, in particular those with severe mental illness, can no longer be ignored but demands urgent targeted and persistent action. Twenty-two recommendations are proposed to facilitate this process.